Novavax’s stock jumps after Biden mentions its COVID-19 vaccine candidate

    0
    104

    Shares of Novavax Inc. NVAX, +16.33% gained 12.1% in trading on Tuesday after President Joe Biden mentioned that the company’s experimental COVID-19 vaccine may be nearing emergency-use authorization in the U.S. “The problem is right now we have to make sure we have other vaccines like Novavax and others coming on,” he said during a speech. “And I think we’ll be in a position to be able to share vaccines with other countries who are in real need. That’s the hope and expectation.” Novavax’s still-investigational COVID-19 vaccine is currently being tested in a Phase 3 clinical trial in Mexico and the U.S. that began in December. (A separate late-stage study in the U.K. is also underway, and early data from that trial found that the vaccine candidate had an overall efficacy rate of 89.7%.) Novavax’s stock has soared 126.0% so far this year, while the S&P 500 SPX, -0.02% is up 11.5%.

    This article was originally published by Marketwatch.com. Read the original article here.

    Previous articleOutside the Box: Biden’s plan to raise capital-gains taxes is good politics but bad economics
    Next article‘Disaster Girl’ just made more than $430,000 selling the NFT of her meme

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here